Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

pared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Notably, future currency fluctuations may negatively impact the profitability of the Group and its ability to reach its objectives. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorite des Marches Financiers.

---------------------------------

[1] International Journal of Cancer. 2009 Mar 15;124(6):1449-56 "IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells." by Brezak MC, Valette A, Quaranta M, Contour-Galc
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... Sept. 30, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 ... Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid ... Use Thereof." The patent, which extends ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The custom ... ISPE Boston Product Show 2014. The Boston Area Chapter ... the 23rd annual, day-long event for Wed., Oct. 1 ... promises to be the largest in ISPE Boston’s long ... upward of 3,000 attendees expected. , HOLLOWAY AMERICA ...
(Date:9/30/2014)... September 30, 2014 UFP Technologies, ... specialty packaging has recently introduced a custom insulated ... Pack . The new insulated shipper solves the ... distribution process. UFP Technologies’ BioShell is a universal ... during storage, handling and shipping. The insulated shipper ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... of a three-part series focusing on the past, present and future of ... to WTNs interview with Nettles in March 2003. , , ... the next six to 12 months, what Dept. of Commerce initiatives would ... I had a meeting with Gov. Doyle a couple of weeks ...
... people who helped North Carolina and Los Angeles become ... of angel investors shared their most effective practices Tuesday ... ,Their techniques included educational programsbut you have to be ... the Council for Entrepreneurial Development , based in ...
... The second annual Wisconsin Entrepreneurs Conference got off to a ... treating at least a hundred entrepreneurs and industry representatives to ... The entrepreneurial boot camp was designed serve both veteran ... success from a panel of seasoned industrialists. , ,Our purpose ...
Cached Biology Technology:WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 2WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 4WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 5Experts share advice for Wisconsin entrepreneur programs 2Experts share advice for Wisconsin entrepreneur programs 3Experts share advice for Wisconsin entrepreneur programs 4Entrepreneurs get crash course for building a successful company 2Entrepreneurs get crash course for building a successful company 3
(Date:9/30/2014)... Health (NIH) awarded Lawrence Livermore National Laboratory (LLNL) ... system that will enable researchers to better understand ... scale. , LLNL,s grant-funded project is part of ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative , ... of the human mind and uncover ways to ...
(Date:9/30/2014)... live in almost any aquatic environment on Earth, but ... species are pushed to the limit. The amount of ... critical for how different species cope in the future, ... of Gothenburg, published in the scientific journal Proceedings ... continues apace thanks to increasing levels of greenhouse gases ...
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2
... researchers from Princeton University and the Drexel University College ... malaria breaks down an important amino acid in its ... By depleting this substance called arginine, the parasite may ... disease. The scientists believe that shedding light on ...
... and University of Malaya (UM) today announced the establishment ... This is the first Centre of its kind in ... communities in terms of their diet and disease, conducting ... environment and health, providing assistance for the national cancer ...
... of the oil in the ocean bubbles up naturally from ... was of no value. Likewise, NASA satellites collect thousands of ... of it gets passed over because no one thinks there ... black gold bubbling up from an otherwise undistinguished mass of ...
Cached Biology News:Malaria parasite zeroes in on molecule to enhance its survival, team finds 2Malaria parasite zeroes in on molecule to enhance its survival, team finds 3Queen's University Belfast improves Malaysian public health 2Scientists find black gold amidst overlooked data 2Scientists find black gold amidst overlooked data 3
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Biology Products: